I was cut off also but was able to catch the missed portions on the archived version.
For AVP-786 he noted the import of the agitation studies is just beginning to catch on with investors. For the first time he noted how royalties were likely to be more important that the outstanding $162 million in milestone payments. That marks a major shift in the company's stance. In the past they had noted the "value" of the deal with Avanir as up to $170M referring only to the milestone payments. That omission significantly undervalued the deal...and that missed value is a big part of why I bought CNCE in the first place.